Your browser doesn't support javascript.
Coccidioidomycosis and COVID-19 Infection. An Analysis from a Single Medical Center Within the Coccidioidal Endemic Area.
Huff, Daniel; Ampel, Neil M; Blair, Janis E.
  • Huff D; Department of Medicine, Mayo Clinic in Arizona, Phoenix, Arizona, USA.
  • Ampel NM; The Division of Infectious Diseases of Mayo Clinic in Arizona, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA.
  • Blair JE; The Division of Infectious Diseases of Mayo Clinic in Arizona, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA. blair.Janis@Mayo.edu.
Mycopathologia ; 187(2-3): 199-204, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1797574
ABSTRACT
At a single medical center, we identified 60 cases of coccidioidomycosis that were coincident with COVID-19 infection. Among these, seven patients developed new or clinically progressive coccidioidomycosis. Receipt of dexamethasone for COVID-19 infection was the only significant risk factor for the progression or development of clinically active coccidioidomycosis in this cohort. All patients survived and none developed disseminated coccidioidomycosis.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Coccidioidomycosis / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Mycopathologia Year: 2022 Document Type: Article Affiliation country: S11046-022-00629-6

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Coccidioidomycosis / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Mycopathologia Year: 2022 Document Type: Article Affiliation country: S11046-022-00629-6